Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868485 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Wayshine Biopharm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT06868485: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Wayshine Biopharm.
NCT06868485 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Wayshine Biopharm. The registered enrollment target is 40 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 18 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868485, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Wayshine Biopharm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Primary Outcome
proportion of patients with a best overall response of complete response or partial response
Conditions Studied
Interventions
- DRUG WSD0922-FU Tablets, Dose level A
- DRUG WSD0922-FU Tablets, Dose level B
Study Locations (18)
Shanghai Municipality
- Shanghai East hospital - Shanghai
- Shanghai Pulmonary Hospital - Shanghai
Nouvelle-Aquitaine
- Centre Hospitalier Universitaire CHU De Limoges - Limoges
- CHU Bordeaux - Centre Francois Magendie - Pessac
California
- FOMAT Oncology - Oxnard
Florida
- Cleveland Clinic Weston Hospital - Weston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Hackensack Meridian Health-Southern Ocean Medical Center - Manahawkin
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06868485 shows while recruiting
NCT06868485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which WSD0922-FU Tablets, Dose level A is the first listed.
NCT06868485 lists 18 locations in 16 states (Shanghai Municipality, Nouvelle-Aquitaine, California).
Frequently Asked Questions
What is clinical trial NCT06868485 about?
NCT06868485 is a clinical study titled "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer". This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Recep...
What is the current status of trial NCT06868485?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-18. Estimated completion is 2027-12-31.
What conditions does trial NCT06868485 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06868485?
The interventions under investigation include: WSD0922-FU Tablets, Dose level A (DRUG), WSD0922-FU Tablets, Dose level B (DRUG).
Who is sponsoring clinical trial NCT06868485?
This trial is sponsored by Wayshine Biopharm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868485 being conducted?
This trial has 18 study locations across California, Florida, Michigan, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868485's enrollment target sits among peer trials
40 360th of 454 higher than 87 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI